<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01843621</url>
  </required_header>
  <id_info>
    <org_study_id>A-13227</org_study_id>
    <secondary_id>GSK 103795</secondary_id>
    <secondary_id>WRAIR 1159</secondary_id>
    <nct_id>NCT01843621</nct_id>
    <nct_alias>NCT00318916</nct_alias>
  </id_info>
  <brief_title>A Phase I/II Trial of a Tetravalent Live Attenuated DEN Vaccine in Flavivirus Antibody Naive Children</brief_title>
  <official_title>A Phase I/II, Open, Five-year, Clinical Follow-up Study of Thai Children Who Participated in Dengue-003 (&quot;A Phase I/II Trial of a Tetravalent Live Attenuated DEN Vaccine in Flavivirus Antibody Naive Children&quot;) With Evaluation of a Booster Dose Given One Year After Primary DEN Vaccination Series</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>U.S. Army Medical Research and Development Command</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>U.S. Army Medical Research and Development Command</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      One year follow-up on immunogenicity and safety of a booster dose of DEN vaccine administered
      approx. 1 year following the second dose
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to find out more about the two doses of dengue vaccine, over a
      five year period, that the children received in the Dengue-003 study and to study a third
      dose of dengue that will be given to the children

        -  Do children still have dengue antibodies intended to provide protection against dengue
           infection one year after the two doses of vaccine given in study Dengue-003?

        -  Were there any major medical problems that appeared as dengue-like symptoms during the
           one year after vaccinations?

        -  Will a third dose of dengue help to further stimulate the part of the immune system
           intended to help protect against dengue infection?

        -  Is a third dose as safe as the first two doses?

        -  Are the local reactions to a third dose of the vaccine similar to what your child
           experienced after the first two doses?
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2005</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2005</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects With Seropositivity Rates for Antibodies to DEN-1 - DEN-4 (ATP Cohort for Immunogenicity)</measure>
    <time_frame>Prebooster Year 1, 30 Days Post Booster, Year 2, and Year 3</time_frame>
    <description>Neutralizing antibodies as measured by plaque reduction neutralization test (seropositivity rates to each dengue virus serotype at Prebooster Year 1, 30 Days Post Booster, Year 2, and Year 3 time points.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMTs) on All Subjects for Antibodies to DEN-1 - DEN-4 (ATP Cohort for Immunogenicity)</measure>
    <time_frame>Prebooster Year 1, 30 Days Post Booster, Year 2, and Year 3</time_frame>
    <description>Neutralizing antibodies as measured by plaque reduction neutralization test (geometric mean titers [GMTs]) to each dengue virus serotype at Prebooster Year 1, 30 Days Post Booster, Year 2, and Year 3 time points.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Solicited Local Adverse Events (AEs) Within 21 Day Follow-up</measure>
    <time_frame>21 days</time_frame>
    <description>Incidence of solicited local symptoms reported during the 21-day post-vaccination (total vaccination cohort).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unsolicited Adverse Events (AEs) Within 31 Days Post Vaccination</measure>
    <time_frame>31 days</time_frame>
    <description>Percentage of subjects reporting unsolicited AEs within 31 days (Day 0-30) after the DEN vaccine dose (total vaccinated cohort)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events (SAE) Within 31 Days Post Vaccination</measure>
    <time_frame>31 days</time_frame>
    <description>Occurrence of SAEs within 31 days (Day 0-30) after vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abnormal Findings Reported During Physical Exam 31-Days Post Vaccination</measure>
    <time_frame>31 days</time_frame>
    <description>Incidence of dengue physical examination findings reported during the 31-day post-vaccination period (total vaccinated cohort)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies 30 Days Post Booster</measure>
    <time_frame>Prebooster year 1, 30 Days Post Booster, Year 2, Year 3</time_frame>
    <description>Monovalent, Bivalent, Trivalent and Tetravalent response for DEN neut. antibodies 30 days post booster dose vaccine (ATP cohort for immunogenicity)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of Dengue Viremia 10 Days After the Dengue Vaccine Dose</measure>
    <time_frame>10 days</time_frame>
    <description>Nested Polymerase Chain Reaction (PCR) for DEN was conducted on day 10 after DEN booster vaccination to evaluate the presence of Dengue viremia 10 days after vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Flavivirus Infection in Terms of Dengue Immunoglobulin M and Immunoglobulin G Per Subject (ATP Cohort for Immunogenicity)</measure>
    <time_frame>1 year, 30 Days Post Booster, 2 years</time_frame>
    <description>The ratio of DEN Immunoglobulin type M and G (IgM:IgG) measured at the time of booster vaccination and 30 days following was used to assess intercurrent flavivirus infection. Flavivirus infection in terms of dengue IgM and IgG and Japanese encephalitis virus (JEV) IgM and IgG is summarized.
Flavivirus immunity= ratio IgM on IgG &lt;1.8 with either IgM or IgM &gt;1:40
If the antibody response is detectable by isotype capture enzyme immunoassay (either the IgM or IgG component â‰¥40 U), its anamnestic character can be inferred from detection of a DEN IgM to IgG ratio of &lt;1.8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Biochemistry and Hematology Parameters Monitored for Alert Levels</measure>
    <time_frame>Year 1 (day 0); Year 1 (day 30); Year 2</time_frame>
    <description>Clinical safety laboratory test were monitored for alert levels. Tests were performed by Laser scattering using Cell Dyn 3500 and Serum chemistry conducted by Kinetic method using Hitachi 717.
Normal Ranges:
Alanine Aminotransferases (ALT): LNL=0 and UNL=30 Aspartate Aminotransferases (AST): LNL=0 and UNL=40 Platelet (PLA): LNL=150000 and UNL=350000 Hematocrit (HC): LNL=35 and UNL=45 Neutrophil (NEU): LNL=1500 and UNL=8000</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Dengue</condition>
  <arm_group>
    <arm_group_label>Total vaccinated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The total vaccinated cohort included all enrolled subjects who received the DEN vaccine F17 for whom data were available. These subjects were Thai children previously enrolled and vaccinated in study Dengue-003</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DEN vaccine F17</intervention_name>
    <description>The dengue booster vaccine was administered subcutaneously in the non-dominant arm (deltoid). The tetravalent, live attenuated DEN F17 vaccine was administered in this study. This pre-transfection formulation contained dengue virus types 1, 2, 3 and 4 (DEN-1, -2, -3 and -4).</description>
    <arm_group_label>Total vaccinated</arm_group_label>
    <other_name>Live attenuated tetravalent dengue (DEN) vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who received two doses of DEN vaccine in the Dengue-003 study

          -  Subjects whos parents signed an informed consent form were eligible for participation
             in the five year follow-up study

        Exclusion Criteria:

          -  None
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>9 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sriluck Simasathien, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Pediatrics, Phramongkutklao Hospital, Bangkok, Thailand</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Gibbons, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Armed Forces Research Institute of Medical Sciences (AFRIMS), Bangkok, Thailand</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Pediatrics, Phramongkutklao Hospital</name>
      <address>
        <city>Phayathai</city>
        <state>Bangkok</state>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>April 22, 2013</study_first_submitted>
  <study_first_submitted_qc>April 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2013</study_first_posted>
  <results_first_submitted>December 29, 2016</results_first_submitted>
  <results_first_submitted_qc>May 15, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 26, 2018</results_first_posted>
  <last_update_submitted>May 15, 2018</last_update_submitted>
  <last_update_submitted_qc>May 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dengue, Vaccine, Thailand</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dengue</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>GSK</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Seven Thai children from the Dengue-03 study will be invited to participate</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Total Vaccinated</title>
          <description>The total vaccinated cohort included all enrolled subjects who received the DEN vaccine F17 for whom data were available. These subjects were Thai children previously enrolled and vaccinated in study Dengue-003
DEN vaccine F17: The dengue booster vaccine was administered subcutaneously in the non-dominant arm (deltoid). The tetravalent, live attenuated DEN F17 vaccine was administered in this study. This pre-transfection formulation contained dengue virus types 1, 2, 3 and 4 (DEN-1, -2, -3 and -4).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Total Vaccinated</title>
          <description>The total vaccinated cohort included all enrolled subjects who received the DEN vaccine F17 for whom data were available. These subjects were Thai children previously enrolled and vaccinated in study Dengue-003
DEN vaccine F17: The dengue booster vaccine was administered subcutaneously in the non-dominant arm (deltoid). The tetravalent, live attenuated DEN F17 vaccine was administered in this study. This pre-transfection formulation contained dengue virus types 1, 2, 3 and 4 (DEN-1, -2, -3 and -4).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.3" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Thailand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With Seropositivity Rates for Antibodies to DEN-1 - DEN-4 (ATP Cohort for Immunogenicity)</title>
        <description>Neutralizing antibodies as measured by plaque reduction neutralization test (seropositivity rates to each dengue virus serotype at Prebooster Year 1, 30 Days Post Booster, Year 2, and Year 3 time points.</description>
        <time_frame>Prebooster Year 1, 30 Days Post Booster, Year 2, and Year 3</time_frame>
        <population>Immunogenicity data for one subject was not included in the ATP analysis due to an asymptomatic, sub-clinical, wild-type DEN-2 virus infection prior to DEN vaccine dose 1</population>
        <group_list>
          <group group_id="O1">
            <title>&gt; 10 ED50</title>
            <description>Seropositivity rates (% of subjects)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Seropositivity Rates for Antibodies to DEN-1 - DEN-4 (ATP Cohort for Immunogenicity)</title>
          <description>Neutralizing antibodies as measured by plaque reduction neutralization test (seropositivity rates to each dengue virus serotype at Prebooster Year 1, 30 Days Post Booster, Year 2, and Year 3 time points.</description>
          <population>Immunogenicity data for one subject was not included in the ATP analysis due to an asymptomatic, sub-clinical, wild-type DEN-2 virus infection prior to DEN vaccine dose 1</population>
          <units>% of subjects</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>N lg to DEN-1: Prebooster Year 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7" lower_limit="0.4" upper_limit="64.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N lg to DEN-1: 30 Days Post Booster</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.3" lower_limit="35.9" upper_limit="99.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N lg to DEN-1: Year 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7" lower_limit="0.4" upper_limit="64.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N lg to DEN-1: Year 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7" lower_limit="22.3" upper_limit="95.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N lg to DEN-2: Prebooster Year 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" lower_limit="11.8" upper_limit="88.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N lg to DEN-2: 30 Days Post Booster</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="54.1" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N lg to DEN-2: Year 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7" lower_limit="22.3" upper_limit="95.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N lg to DEN-2: Year 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.3" lower_limit="35.9" upper_limit="99.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N lg to DEN-3: Prebooster Year 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3" lower_limit="4.3" upper_limit="77.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N lg to DEN-3: 30 Days Post Booster</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="54.1" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N lg to DEN-3: Year 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3" lower_limit="4.3" upper_limit="77.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N lg to DEN-3: Year 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" lower_limit="11.8" upper_limit="88.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N lg to DEN-4: Prebooster Year 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" lower_limit="11.8" upper_limit="88.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N lg to DEN-4: 30 days Post Booster</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="54.1" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N lg to DEN-4: Year 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" lower_limit="11.8" upper_limit="88.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N lg to DEN-4: Year 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="54.1" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers (GMTs) on All Subjects for Antibodies to DEN-1 - DEN-4 (ATP Cohort for Immunogenicity)</title>
        <description>Neutralizing antibodies as measured by plaque reduction neutralization test (geometric mean titers [GMTs]) to each dengue virus serotype at Prebooster Year 1, 30 Days Post Booster, Year 2, and Year 3 time points.</description>
        <time_frame>Prebooster Year 1, 30 Days Post Booster, Year 2, and Year 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Geometric Mean Titer (GMT)</title>
            <description>Geometric mean antibody titer value</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) on All Subjects for Antibodies to DEN-1 - DEN-4 (ATP Cohort for Immunogenicity)</title>
          <description>Neutralizing antibodies as measured by plaque reduction neutralization test (geometric mean titers [GMTs]) to each dengue virus serotype at Prebooster Year 1, 30 Days Post Booster, Year 2, and Year 3 time points.</description>
          <units>GMTs</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>N lg to DEN-1: Pre-booster Year 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" lower_limit="3.8" upper_limit="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N lg to DEN-1: 30 Days Post-booster</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.2" lower_limit="6.6" upper_limit="121.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N lg to DEN-1: Year 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" lower_limit="3.1" upper_limit="15.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N lg to DEN-1: Year 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.0" lower_limit="5.2" upper_limit="63.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N lg to DEN-2: Pre-booster Year 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.8" lower_limit="3.4" upper_limit="82.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N lg to DEN-2: 30 Day Post-booster</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.4" lower_limit="24.0" upper_limit="370.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N lg to DEN-2: Year 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.8" lower_limit="4.6" upper_limit="92.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N lg to DEN-2: Year 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.3" lower_limit="7.0" upper_limit="186.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N lg to DEN-3: Pre-booster Year 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8" lower_limit="2.1" upper_limit="77.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N lg to DEN-3: 30 Days post-booster</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.2" lower_limit="9.3" upper_limit="487.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N lg to DEN-3: Year 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4" lower_limit="2.8" upper_limit="31.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N lg to DEN-3: Year 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.9" lower_limit="4.1" upper_limit="41.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N lg to DEN-4: Pre-booster Year 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.0" lower_limit="3.6" upper_limit="200.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N lg to DEN-4: 30 Days Post-booster</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112.0" lower_limit="26.5" upper_limit="473.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N lg to DEN-4: Year 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.4" lower_limit="3.5" upper_limit="182.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N lg to DEN-4: Year 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.4" lower_limit="23.9" upper_limit="207.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Solicited Local Adverse Events (AEs) Within 21 Day Follow-up</title>
        <description>Incidence of solicited local symptoms reported during the 21-day post-vaccination (total vaccination cohort).</description>
        <time_frame>21 days</time_frame>
        <population>Incidence of solicited local symptoms reported during the 21-day post-vaccination (total vaccination cohort).</population>
        <group_list>
          <group group_id="O1">
            <title>Total Vaccinated</title>
            <description>The total vaccinated cohort included all enrolled subjects who received the DEN vaccine F17 for whom data were available. These subjects were Thai children previously enrolled and vaccinated in study Dengue-003
DEN vaccine F17: The dengue booster vaccine was administered subcutaneously in the non-dominant arm (deltoid). The tetravalent, live attenuated DEN F17 vaccine was administered in this study. This pre-transfection formulation contained dengue virus types 1, 2, 3 and 4 (DEN-1, -2, -3 and -4).</description>
          </group>
        </group_list>
        <measure>
          <title>Solicited Local Adverse Events (AEs) Within 21 Day Follow-up</title>
          <description>Incidence of solicited local symptoms reported during the 21-day post-vaccination (total vaccination cohort).</description>
          <population>Incidence of solicited local symptoms reported during the 21-day post-vaccination (total vaccination cohort).</population>
          <units>Adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain: All</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: All</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: All</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Unsolicited Adverse Events (AEs) Within 31 Days Post Vaccination</title>
        <description>Percentage of subjects reporting unsolicited AEs within 31 days (Day 0-30) after the DEN vaccine dose (total vaccinated cohort)</description>
        <time_frame>31 days</time_frame>
        <population>Percentage of subjects reporting unsolicited AEs within 31 days (Day 0-30) after the DEN vaccine dose (total vaccinated cohort)</population>
        <group_list>
          <group group_id="O1">
            <title>Total Vaccinated</title>
            <description>The total vaccinated cohort included all enrolled subjects who received the DEN vaccine F17 for whom data were available. These subjects were Thai children previously enrolled and vaccinated in study Dengue-003
DEN vaccine F17: The dengue booster vaccine was administered subcutaneously in the non-dominant arm (deltoid). The tetravalent, live attenuated DEN F17 vaccine was administered in this study. This pre-transfection formulation contained dengue virus types 1, 2, 3 and 4 (DEN-1, -2, -3 and -4).</description>
          </group>
        </group_list>
        <measure>
          <title>Unsolicited Adverse Events (AEs) Within 31 Days Post Vaccination</title>
          <description>Percentage of subjects reporting unsolicited AEs within 31 days (Day 0-30) after the DEN vaccine dose (total vaccinated cohort)</description>
          <population>Percentage of subjects reporting unsolicited AEs within 31 days (Day 0-30) after the DEN vaccine dose (total vaccinated cohort)</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At Least One Symptom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.7" lower_limit="42.1" upper_limit="99.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infections and Infestations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3" lower_limit="0.4" upper_limit="57.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injury, Poisoning and Procedural Complications</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3" lower_limit="0.4" upper_limit="57.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nervous System Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.9" lower_limit="9.9" upper_limit="81.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Renal and Urinary Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3" lower_limit="0.4" upper_limit="57.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory, Thoracic and Mediastinal Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.6" lower_limit="3.7" upper_limit="71.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serious Adverse Events (SAE) Within 31 Days Post Vaccination</title>
        <description>Occurrence of SAEs within 31 days (Day 0-30) after vaccination</description>
        <time_frame>31 days</time_frame>
        <population>Occurrence of SAEs within 31 days (Day 0-30) after vaccination</population>
        <group_list>
          <group group_id="O1">
            <title>Total Vaccinated</title>
            <description>The total vaccinated cohort included all enrolled subjects who received the DEN vaccine F17 for whom data were available. These subjects were Thai children previously enrolled and vaccinated in study Dengue-003
DEN vaccine F17: The dengue booster vaccine was administered subcutaneously in the non-dominant arm (deltoid). The tetravalent, live attenuated DEN F17 vaccine was administered in this study. This pre-transfection formulation contained dengue virus types 1, 2, 3 and 4 (DEN-1, -2, -3 and -4).</description>
          </group>
        </group_list>
        <measure>
          <title>Serious Adverse Events (SAE) Within 31 Days Post Vaccination</title>
          <description>Occurrence of SAEs within 31 days (Day 0-30) after vaccination</description>
          <population>Occurrence of SAEs within 31 days (Day 0-30) after vaccination</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Abnormal Findings Reported During Physical Exam 31-Days Post Vaccination</title>
        <description>Incidence of dengue physical examination findings reported during the 31-day post-vaccination period (total vaccinated cohort)</description>
        <time_frame>31 days</time_frame>
        <population>Incidence of dengue physical examination findings reported during the 31-day post-vaccination period (total vaccinated cohort)</population>
        <group_list>
          <group group_id="O1">
            <title>Total Vaccinated</title>
            <description>The total vaccinated cohort included all enrolled subjects who received the DEN vaccine F17 for whom data were available. These subjects were Thai children previously enrolled and vaccinated in study Dengue-003
DEN vaccine F17: The dengue booster vaccine was administered subcutaneously in the non-dominant arm (deltoid). The tetravalent, live attenuated DEN F17 vaccine was administered in this study. This pre-transfection formulation contained dengue virus types 1, 2, 3 and 4 (DEN-1, -2, -3 and -4).</description>
          </group>
        </group_list>
        <measure>
          <title>Abnormal Findings Reported During Physical Exam 31-Days Post Vaccination</title>
          <description>Incidence of dengue physical examination findings reported during the 31-day post-vaccination period (total vaccinated cohort)</description>
          <population>Incidence of dengue physical examination findings reported during the 31-day post-vaccination period (total vaccinated cohort)</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.9" lower_limit="9.9" upper_limit="86.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies 30 Days Post Booster</title>
        <description>Monovalent, Bivalent, Trivalent and Tetravalent response for DEN neut. antibodies 30 days post booster dose vaccine (ATP cohort for immunogenicity)</description>
        <time_frame>Prebooster year 1, 30 Days Post Booster, Year 2, Year 3</time_frame>
        <population>Monovalent, Bivalent, Trivalent and Tetravalent response for DEN neut. antibodies 30 days post booster dose vaccine (ATP cohort for immunogenicity). Immunogenicity data for one subject was not included in the ATP analysis due to an asymptomatic, sub-clinical, wild-type DEN-2 virus infection prior to DEN vaccine dose 1</population>
        <group_list>
          <group group_id="O1">
            <title>Total Vaccinated</title>
            <description>The total vaccinated cohort included all enrolled subjects who received the DEN vaccine F17 for whom data were available. These subjects were Thai children previously enrolled and vaccinated in study Dengue-003
DEN vaccine F17: The dengue booster vaccine was administered subcutaneously in the non-dominant arm (deltoid). The tetravalent, live attenuated DEN F17 vaccine was administered in this study. This pre-transfection formulation contained dengue virus types 1, 2, 3 and 4 (DEN-1, -2, -3 and -4).</description>
          </group>
        </group_list>
        <measure>
          <title>Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies 30 Days Post Booster</title>
          <description>Monovalent, Bivalent, Trivalent and Tetravalent response for DEN neut. antibodies 30 days post booster dose vaccine (ATP cohort for immunogenicity)</description>
          <population>Monovalent, Bivalent, Trivalent and Tetravalent response for DEN neut. antibodies 30 days post booster dose vaccine (ATP cohort for immunogenicity). Immunogenicity data for one subject was not included in the ATP analysis due to an asymptomatic, sub-clinical, wild-type DEN-2 virus infection prior to DEN vaccine dose 1</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-Booster Year 1: Monovalent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.67" lower_limit="0.42" upper_limit="64.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-Booster Year 1: Bivalent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.33" lower_limit="4.33" upper_limit="77.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-Booster Year 1: Trivalent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="0.00" upper_limit="45.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-Booster Year 1: Tetravalent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.67" lower_limit="0.42" upper_limit="64.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 Days Post Booster: Monovalent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="0.00" upper_limit="45.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 Days Post Booster: Bivalent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="0.00" upper_limit="45.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 Days post Booster: Trivalent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.67" lower_limit="0.42" upper_limit="64.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 Days Post Booster: Tetravalent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.33" lower_limit="35.88" upper_limit="99.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2: Monovalent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.33" lower_limit="4.33" upper_limit="77.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2: Bivalent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.33" lower_limit="4.33" upper_limit="77.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2: Trivalent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="0.00" upper_limit="45.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2: Tetravalent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.67" lower_limit="0.42" upper_limit="64.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 3: Monovalent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="0.00" upper_limit="45.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 3: Bivalent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.33" lower_limit="4.33" upper_limit="77.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 3: Trivalent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.33" lower_limit="4.33" upper_limit="77.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 3: Tetravalent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.33" lower_limit="4.33" upper_limit="77.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Presence of Dengue Viremia 10 Days After the Dengue Vaccine Dose</title>
        <description>Nested Polymerase Chain Reaction (PCR) for DEN was conducted on day 10 after DEN booster vaccination to evaluate the presence of Dengue viremia 10 days after vaccination</description>
        <time_frame>10 days</time_frame>
        <population>Nested PCR for DEN was conducted on day 10 after DEN booster vaccination to evaluate the presence of Dengue viremia 10 days after vaccination</population>
        <group_list>
          <group group_id="O1">
            <title>Total Vaccinated</title>
            <description>The total vaccinated cohort included all enrolled subjects who received the DEN vaccine F17 for whom data were available. These subjects were Thai children previously enrolled and vaccinated in study Dengue-003
DEN vaccine F17: The dengue booster vaccine was administered subcutaneously in the non-dominant arm (deltoid). The tetravalent, live attenuated DEN F17 vaccine was administered in this study. This pre-transfection formulation contained dengue virus types 1, 2, 3 and 4 (DEN-1, -2, -3 and -4).</description>
          </group>
        </group_list>
        <measure>
          <title>Presence of Dengue Viremia 10 Days After the Dengue Vaccine Dose</title>
          <description>Nested Polymerase Chain Reaction (PCR) for DEN was conducted on day 10 after DEN booster vaccination to evaluate the presence of Dengue viremia 10 days after vaccination</description>
          <population>Nested PCR for DEN was conducted on day 10 after DEN booster vaccination to evaluate the presence of Dengue viremia 10 days after vaccination</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Flavivirus Infection in Terms of Dengue Immunoglobulin M and Immunoglobulin G Per Subject (ATP Cohort for Immunogenicity)</title>
        <description>The ratio of DEN Immunoglobulin type M and G (IgM:IgG) measured at the time of booster vaccination and 30 days following was used to assess intercurrent flavivirus infection. Flavivirus infection in terms of dengue IgM and IgG and Japanese encephalitis virus (JEV) IgM and IgG is summarized.
Flavivirus immunity= ratio IgM on IgG &lt;1.8 with either IgM or IgM &gt;1:40
If the antibody response is detectable by isotype capture enzyme immunoassay (either the IgM or IgG component â‰¥40 U), its anamnestic character can be inferred from detection of a DEN IgM to IgG ratio of &lt;1.8.</description>
        <time_frame>1 year, 30 Days Post Booster, 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ratio IgM and IgG</title>
            <description>Ratio of Dengue (DEN) IgM and IgG and Japanese encephalitis virus (JEV) IgM and IgG (ATP cohort for immunogenicity)</description>
          </group>
        </group_list>
        <measure>
          <title>Flavivirus Infection in Terms of Dengue Immunoglobulin M and Immunoglobulin G Per Subject (ATP Cohort for Immunogenicity)</title>
          <description>The ratio of DEN Immunoglobulin type M and G (IgM:IgG) measured at the time of booster vaccination and 30 days following was used to assess intercurrent flavivirus infection. Flavivirus infection in terms of dengue IgM and IgG and Japanese encephalitis virus (JEV) IgM and IgG is summarized.
Flavivirus immunity= ratio IgM on IgG &lt;1.8 with either IgM or IgM &gt;1:40
If the antibody response is detectable by isotype capture enzyme immunoassay (either the IgM or IgG component â‰¥40 U), its anamnestic character can be inferred from detection of a DEN IgM to IgG ratio of &lt;1.8.</description>
          <units>Flavivirus immunity ratio</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DEN Subject 2: 1 Year Ratio</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DEN Subject 2: 30 Days Post Booster Ratio</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DEN Subject 2: Year 2 Ratio</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>JEV Subject 2: Year 1 Ratio</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>JEV Subject 2: 30 Days Post Booster Ratio</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>JEV Subject 2: Year 2 Ratio</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DEN Subject 3: Year 1 Ratio</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DEN Subject 3: 30 Days Post Booster Ratio</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DEN Subject 3: Year 2 Ratio</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>JEV Subject 3: Year 1 Ratio</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>JEV Subject 3: 30 Days Post Booster Ratio</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>JEV Subject 3: Year 2 Ratio</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DEN Subject 4: Year 1 Ratio</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DEN Subject 4: 30 Days Post Booster Ratio</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DEN Subject 4: Year 2 Ratio</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>JEV Subject 4: Year 1 Ratio</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>JEV Subject 4: Year 2 Ratio</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DEN Subject 5: Year 1 Ratio</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DEN Subject 5: 30 Days Post Booster Ratio</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DEN Subject 5: Year 2 Ratio</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>JEV Subject 5: Year 1 Ratio</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>JEV Subject 5: 30 Days Post Booster Ratio</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>JEV Subject 5: Year 2 Ratio</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DEN Subject 6: Year 1 Ratio</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DEN Subject 6: 30 Days Post Booster Ratio</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DEN Subject 6: Year 2 Ratio</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>JEV Subject 6: Year 1 Ratio</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>JEV Subject 6: 30 Days Post Booster Ratio</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>JEV Subject 6: Year 2 Ratio</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DEN Subject 7: Year 1 Ratio</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DEN Subject 7: 30 Days Post Booster Ratio</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DEN Subject 7: Year 2 Ratio</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>JEV Subject 7: Year 1 Ratio</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>JEV Subject 7: 30 Days Post Ratio</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>JEV Subject 7: Year 2 Ratio</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Biochemistry and Hematology Parameters Monitored for Alert Levels</title>
        <description>Clinical safety laboratory test were monitored for alert levels. Tests were performed by Laser scattering using Cell Dyn 3500 and Serum chemistry conducted by Kinetic method using Hitachi 717.
Normal Ranges:
Alanine Aminotransferases (ALT): LNL=0 and UNL=30 Aspartate Aminotransferases (AST): LNL=0 and UNL=40 Platelet (PLA): LNL=150000 and UNL=350000 Hematocrit (HC): LNL=35 and UNL=45 Neutrophil (NEU): LNL=1500 and UNL=8000</description>
        <time_frame>Year 1 (day 0); Year 1 (day 30); Year 2</time_frame>
        <population>Tests were performed by Laser scattering using Cell Dyn 3500 and Serum chemistry conducted by Kinetic method using Hitachi 717. Tests included ALT, AST, PLA, HC, and NEU levels.</population>
        <group_list>
          <group group_id="O1">
            <title>ALT Level</title>
            <description>Normal Range = 0-30</description>
          </group>
          <group group_id="O2">
            <title>AST Level</title>
            <description>Normal Range = 0-40</description>
          </group>
          <group group_id="O3">
            <title>PLA Level</title>
            <description>Normal Range = 150000-350000</description>
          </group>
          <group group_id="O4">
            <title>HC Level</title>
            <description>Normal Range = 35-45</description>
          </group>
          <group group_id="O5">
            <title>NEU Level</title>
            <description>Normal Range = 1500-8000</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Biochemistry and Hematology Parameters Monitored for Alert Levels</title>
          <description>Clinical safety laboratory test were monitored for alert levels. Tests were performed by Laser scattering using Cell Dyn 3500 and Serum chemistry conducted by Kinetic method using Hitachi 717.
Normal Ranges:
Alanine Aminotransferases (ALT): LNL=0 and UNL=30 Aspartate Aminotransferases (AST): LNL=0 and UNL=40 Platelet (PLA): LNL=150000 and UNL=350000 Hematocrit (HC): LNL=35 and UNL=45 Neutrophil (NEU): LNL=1500 and UNL=8000</description>
          <population>Tests were performed by Laser scattering using Cell Dyn 3500 and Serum chemistry conducted by Kinetic method using Hitachi 717. Tests included ALT, AST, PLA, HC, and NEU levels.</population>
          <units>U/L</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subject 1: Year 1, Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="494000"/>
                    <measurement group_id="O4" value="37"/>
                    <measurement group_id="O5" value="2820"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject 1: Year 1, Day 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="369000"/>
                    <measurement group_id="O4" value="37.1"/>
                    <measurement group_id="O5" value="3020"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject 1: Year 1, Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="411000"/>
                    <measurement group_id="O4" value="39.3"/>
                    <measurement group_id="O5" value="3000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject 1: Year 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="502000"/>
                    <measurement group_id="O4" value="38.9"/>
                    <measurement group_id="O5" value="4790"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject 2: Year 1, Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="293000"/>
                    <measurement group_id="O4" value="36.1"/>
                    <measurement group_id="O5" value="3210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject 2: Year 1, Day 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="248000"/>
                    <measurement group_id="O4" value="36.9"/>
                    <measurement group_id="O5" value="2770"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject 2: Year 1, Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="296000"/>
                    <measurement group_id="O4" value="35.9"/>
                    <measurement group_id="O5" value="3070"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject 2: Year 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="323000"/>
                    <measurement group_id="O4" value="38.4"/>
                    <measurement group_id="O5" value="2400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject 3: Year 1, Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="270000"/>
                    <measurement group_id="O4" value="39.3"/>
                    <measurement group_id="O5" value="2580"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject 3: Year 1, Day 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="272000"/>
                    <measurement group_id="O4" value="41.8"/>
                    <measurement group_id="O5" value="3750"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject 3: Year 1, Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="303000"/>
                    <measurement group_id="O4" value="42.3"/>
                    <measurement group_id="O5" value="4380"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject 3: Year 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="306000"/>
                    <measurement group_id="O4" value="40.4"/>
                    <measurement group_id="O5" value="5170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject 4: Year 1, Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="280000"/>
                    <measurement group_id="O4" value="38.8"/>
                    <measurement group_id="O5" value="3320"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject 4: Year 1, Day 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="253000"/>
                    <measurement group_id="O4" value="39.9"/>
                    <measurement group_id="O5" value="3460"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject 4: Year 1, Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="297000"/>
                    <measurement group_id="O4" value="41.8"/>
                    <measurement group_id="O5" value="3320"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject 4: Year 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="231000"/>
                    <measurement group_id="O4" value="43.1"/>
                    <measurement group_id="O5" value="3900"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject 5: Year 1, Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="403000"/>
                    <measurement group_id="O4" value="39"/>
                    <measurement group_id="O5" value="3950"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject 5: Year 1, Day 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="415000"/>
                    <measurement group_id="O4" value="40.2"/>
                    <measurement group_id="O5" value="4580"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject 5: Year 1, Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="329000"/>
                    <measurement group_id="O4" value="38.8"/>
                    <measurement group_id="O5" value="2970"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject 5: Year 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="346000"/>
                    <measurement group_id="O4" value="36.6"/>
                    <measurement group_id="O5" value="5920"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject 6: Year 1, Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="440000"/>
                    <measurement group_id="O4" value="36.6"/>
                    <measurement group_id="O5" value="3020"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject 6, Year 1, Day 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="434000"/>
                    <measurement group_id="O4" value="38"/>
                    <measurement group_id="O5" value="3390"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject 6, Year 1, Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="417000"/>
                    <measurement group_id="O4" value="35.4"/>
                    <measurement group_id="O5" value="2690"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject 6, Year 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="461000"/>
                    <measurement group_id="O4" value="39.7"/>
                    <measurement group_id="O5" value="3840"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject 7: Year 1, Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="244000"/>
                    <measurement group_id="O4" value="38.6"/>
                    <measurement group_id="O5" value="3460"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject 7: Year 1, Day 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="238000"/>
                    <measurement group_id="O4" value="37.1"/>
                    <measurement group_id="O5" value="3050"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject 7: Year 1, Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="270000"/>
                    <measurement group_id="O4" value="38.4"/>
                    <measurement group_id="O5" value="2940"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject 7, Year 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="311000"/>
                    <measurement group_id="O4" value="41.4"/>
                    <measurement group_id="O5" value="4240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>21 days post vaccination period following each dose</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Total Vaccinated</title>
          <description>The total vaccinated cohort included all enrolled subjects who received the DEN vaccine F17 for whom data were available. These subjects were Thai children previously enrolled and vaccinated in study Dengue-003
DEN vaccine F17: The dengue booster vaccine was administered subcutaneously in the non-dominant arm (deltoid). The tetravalent, live attenuated DEN F17 vaccine was administered in this study. This pre-transfection formulation contained dengue virus types 1, 2, 3 and 4 (DEN-1, -2, -3 and -4).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Pain behind eyes</sub_title>
                <description>&lt; 2 days</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pain behind eyes</sub_title>
                <description>&gt; 2 days</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <description>&lt; 2 days</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <description>&gt; 2 days</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <description>&lt; 2 days</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Abdominial Pain</sub_title>
                <description>&gt; 2 days</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>&lt; 2 days</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>&gt; 2 days</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>&lt; 2 days</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>&gt; 2 days</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>&lt; 2 days</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>&gt; 2 days</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Fever (Axillary)</sub_title>
                <description>&lt; 2 days</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Fever (Axillary)</sub_title>
                <description>&gt; 2 days</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <description>&lt; 2 days</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <description>&gt; 2 days</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Muscle aches</sub_title>
                <description>&lt; 2 days</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Muscle aches</sub_title>
                <description>&gt; 2 days</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>&lt; 2 days</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>&gt; 2 days</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <description>&lt; 2 days</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <description>&gt; 2 days</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <description>&lt; 2 days</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <description>&gt; 2 days</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sriluck Simasathien, MD</name_or_title>
      <organization>Dept of Pediatrics, Pharmongkutklao Hospital, Bankok, Thailand</organization>
      <phone>66-2-644-8971</phone>
      <email>ssriluck@yahoo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

